title: Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy.
abstract: Interleukin-2 (IL-2) immunotherapy resulted in the development of inflammatory arthritis in three male patients with metastatic cancer. Two patients developed a clinical picture consistent with rheumatoid arthritis. A third patient with a remote history of Reiter's syndrome developed a recrudescence of an inflammatory arthritis after treatment with IL-2. The clinical, laboratory, and histologic data on the patients and the potential pathophysiologic mechanisms are discussed.
authors.affiliation: Department of Medicine, New England Medical Center, Boston, Massachusetts 02111.
authors.forename: E M
authors.initials: EM
authors.lastname: Massarotti
authors.forename: N Y
authors.initials: NY
authors.lastname: Liu
authors.forename: J
authors.initials: J
authors.lastname: Mier
authors.forename: M B
authors.initials: MB
authors.lastname: Atkins
mesh_terms: D000328:Adult; D000974:Antibodies, Antinuclear / Q000097:blood; D001168:Arthritis / Q000097:blood / Q000139:chemically induced* / Q000276:immunology; D016918:Arthritis, Reactive / Q000150:complications; D001706:Biopsy; D006650:Histocompatibility Testing; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000503:physiopathology / Q000628:therapy; D010641:Phenotype; D012074:Remission Induction; D012217:Rheumatoid Factor / Q000097:blood; D013582:Synovial Fluid / Q000737:chemistry; D013583:Synovial Membrane / Q000473:pathology
chemical_list: D000974:Antibodies, Antinuclear; D007376:Interleukin-2; D012217:Rheumatoid Factor